JP2008540389A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008540389A5 JP2008540389A5 JP2008509500A JP2008509500A JP2008540389A5 JP 2008540389 A5 JP2008540389 A5 JP 2008540389A5 JP 2008509500 A JP2008509500 A JP 2008509500A JP 2008509500 A JP2008509500 A JP 2008509500A JP 2008540389 A5 JP2008540389 A5 JP 2008540389A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound according
- optionally substituted
- alkyl
- bond
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 25
- 125000004122 cyclic group Chemical group 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 125000002950 monocyclic group Chemical group 0.000 claims description 5
- 125000002619 bicyclic group Chemical group 0.000 claims description 3
- 125000000165 tricyclic carbocycle group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- -1 N-methylpiperidin-4-yl Chemical group 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000006413 ring segment Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000002843 carboxylic acid group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000004185 ester group Chemical group 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 150000003568 thioethers Chemical class 0.000 claims 2
- BLWWHQCJSVHDJK-QFIPXVFZSA-N (2s)-2-[[3-[[8-(hydroxyamino)-8-oxooctanoyl]amino]phenyl]methylamino]-2-phenylacetic acid Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC(CN[C@H](C(O)=O)C=2C=CC=CC=2)=C1 BLWWHQCJSVHDJK-QFIPXVFZSA-N 0.000 claims 1
- GFQLAZSQPSUKKD-SFHVURJKSA-N (2s)-2-[[3-[[8-(hydroxyamino)-8-oxooctanoyl]amino]phenyl]methylamino]-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound CC(C)(C)OC[C@@H](C(O)=O)NCC1=CC=CC(NC(=O)CCCCCCC(=O)NO)=C1 GFQLAZSQPSUKKD-SFHVURJKSA-N 0.000 claims 1
- DPUPCCLYBOVSNL-SFHVURJKSA-N (2s)-2-[[3-[[8-(hydroxyamino)-8-oxooctanoyl]amino]phenyl]methylamino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NCC1=CC=CC(NC(=O)CCCCCCC(=O)NO)=C1 DPUPCCLYBOVSNL-SFHVURJKSA-N 0.000 claims 1
- BKOTWGYGBLTPKM-QFIPXVFZSA-N (2s)-2-[[4-[[8-(hydroxyamino)-8-oxooctanoyl]amino]phenyl]methylamino]-2-phenylacetic acid Chemical compound C1=CC(NC(=O)CCCCCCC(=O)NO)=CC=C1CN[C@H](C(O)=O)C1=CC=CC=C1 BKOTWGYGBLTPKM-QFIPXVFZSA-N 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 102000013392 Carboxylesterase Human genes 0.000 claims 1
- 108010051152 Carboxylesterase Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000004419 alkynylene group Chemical group 0.000 claims 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 claims 1
- 235000008206 alpha-amino acids Nutrition 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 230000009702 cancer cell proliferation Effects 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- CAFYVKHSHZKTTO-MHZLTWQESA-N cyclopentyl (2s)-2-[[3-[[8-(hydroxyamino)-8-oxooctanoyl]amino]phenyl]methylamino]-2-phenylacetate Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC(CN[C@H](C(=O)OC2CCCC2)C=2C=CC=CC=2)=C1 CAFYVKHSHZKTTO-MHZLTWQESA-N 0.000 claims 1
- NJSXINSJGRZADK-QHCPKHFHSA-N cyclopentyl (2s)-2-[[3-[[8-(hydroxyamino)-8-oxooctanoyl]amino]phenyl]methylamino]-3-[(2-methylpropan-2-yl)oxy]propanoate Chemical compound N([C@@H](COC(C)(C)C)C(=O)OC1CCCC1)CC1=CC=CC(NC(=O)CCCCCCC(=O)NO)=C1 NJSXINSJGRZADK-QHCPKHFHSA-N 0.000 claims 1
- QMGXAAVAXIEBEX-QHCPKHFHSA-N cyclopentyl (2s)-2-[[3-[[8-(hydroxyamino)-8-oxooctanoyl]amino]phenyl]methylamino]-4-methylpentanoate Chemical compound N([C@@H](CC(C)C)C(=O)OC1CCCC1)CC1=CC=CC(NC(=O)CCCCCCC(=O)NO)=C1 QMGXAAVAXIEBEX-QHCPKHFHSA-N 0.000 claims 1
- GLNWREBYRLDPQP-MHZLTWQESA-N cyclopentyl (2s)-2-[[4-[[8-(hydroxyamino)-8-oxooctanoyl]amino]phenyl]methylamino]-2-phenylacetate Chemical compound C1=CC(NC(=O)CCCCCCC(=O)NO)=CC=C1CN[C@@H](C=1C=CC=CC=1)C(=O)OC1CCCC1 GLNWREBYRLDPQP-MHZLTWQESA-N 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 229920000155 polyglutamine Polymers 0.000 claims 1
- 108010040003 polyglutamine Proteins 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0509223A GB0509223D0 (en) | 2005-05-05 | 2005-05-05 | Enzyme inhibitors |
| GB0509223.4 | 2005-05-05 | ||
| PCT/GB2006/001605 WO2006117549A1 (en) | 2005-05-05 | 2006-05-04 | Enzyme inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008540389A JP2008540389A (ja) | 2008-11-20 |
| JP2008540389A5 true JP2008540389A5 (enExample) | 2009-07-02 |
| JP5405820B2 JP5405820B2 (ja) | 2014-02-05 |
Family
ID=34685155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008509500A Expired - Fee Related JP5405820B2 (ja) | 2005-05-05 | 2006-05-04 | 酵素阻害剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US7939666B2 (enExample) |
| EP (2) | EP1879895B1 (enExample) |
| JP (1) | JP5405820B2 (enExample) |
| KR (1) | KR101307815B1 (enExample) |
| CN (1) | CN101133060B (enExample) |
| AT (1) | ATE512150T1 (enExample) |
| AU (1) | AU2006243065B2 (enExample) |
| BR (1) | BRPI0607410A2 (enExample) |
| CA (1) | CA2599411C (enExample) |
| DK (1) | DK1879895T3 (enExample) |
| ES (1) | ES2367369T3 (enExample) |
| GB (1) | GB0509223D0 (enExample) |
| IL (1) | IL185580A (enExample) |
| MX (1) | MX2007010456A (enExample) |
| NZ (1) | NZ560289A (enExample) |
| PL (1) | PL1879895T3 (enExample) |
| PT (1) | PT1879895E (enExample) |
| WO (1) | WO2006117549A1 (enExample) |
| ZA (1) | ZA200707091B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003078448A1 (en) | 2002-03-13 | 2003-09-25 | Signum Biosciences, Inc. | Modulation of protein methylation and phosphoprotein phosphate |
| US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| WO2006084033A1 (en) | 2005-02-03 | 2006-08-10 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| GB0509223D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| MX2007013257A (es) * | 2005-05-05 | 2008-01-21 | Chroma Therapeutics Ltd | Conjugados de ester de alfa-aminoacido-farmaco hidrolizables por carboxilesterasa. |
| GB0509225D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of enzymatic activity |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
| CA2668070A1 (en) | 2006-10-30 | 2008-05-08 | Chroma Therapeutics Ltd. | Hydroxamates as inhibitors of histone deacetylase |
| GB0803747D0 (en) | 2008-02-29 | 2008-04-09 | Martin | Enzyme and receptor modulation |
| GB0903480D0 (en) | 2009-02-27 | 2009-04-08 | Chroma Therapeutics Ltd | Enzyme Inhibitors |
| JP5838157B2 (ja) * | 2009-07-22 | 2015-12-24 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ | Ｈｄａｃ阻害剤およびそれを用いる治療法 |
| JP5947724B2 (ja) * | 2009-12-21 | 2016-07-06 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | シクロフィリンの新しいインヒビター及びその使用 |
| GB201009853D0 (en) | 2010-06-11 | 2010-07-21 | Chroma Therapeutics Ltd | HSP90 inhibitors |
| ES2402252B1 (es) * | 2011-09-26 | 2014-03-10 | Universidad De Granada | Compuesto con actividad antileishmania |
| WO2013062344A1 (en) * | 2011-10-28 | 2013-05-02 | Chong Kun Dang Pharmaceutical Corp. | Hydroxamate derivatives for hdac inhibitor, and the pharmaceutical composition comprising thereof |
| GB201211310D0 (en) | 2012-06-26 | 2012-08-08 | Chroma Therapeutics Ltd | CSF-1R kinase inhibitors |
| SI3222616T1 (sl) | 2012-10-17 | 2019-10-30 | Macrophage Pharma Ltd | N-(2-(4-(6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1(2H)-IL)-3,5- difluorofenil)etil)-L-alanin in njegov terbutil ester |
| CN103172540B (zh) * | 2013-03-18 | 2015-07-01 | 潍坊博创国际生物医药研究院 | 苯甘氨酸类组蛋白去乙酰酶抑制剂及其制备方法和应用 |
| WO2016126726A1 (en) | 2015-02-02 | 2016-08-11 | Forma Therapeutics, Inc. | Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors |
| TW201629026A (zh) | 2015-02-02 | 2016-08-16 | 佛瑪治療公司 | 作為ｈｄａｃ抑制劑的３－烷基雙環［４，５，０］異羥肟酸 |
| CN109476631B (zh) * | 2016-03-22 | 2021-04-06 | 国家健康与医学研究院 | 新衍生物及其作为胱天蛋白酶-2的选择性抑制剂的用途 |
| WO2017216297A1 (en) | 2016-06-16 | 2017-12-21 | Glaxosmithkline Intellectual Property Development Limited | Dosage regimen |
| US10555935B2 (en) | 2016-06-17 | 2020-02-11 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors |
| GB201713975D0 (en) | 2017-08-31 | 2017-10-18 | Macrophage Pharma Ltd | Medical use |
| TWI650139B (zh) * | 2017-10-11 | 2019-02-11 | 行政院原子能委員會核能硏究所 | 含有放射性同位素氟的異羥肟酸類造影劑、其製備方法及其用途 |
| WO2020013116A1 (ja) * | 2018-07-10 | 2020-01-16 | 京都薬品工業株式会社 | Ｐｔｐ－１ｂ阻害剤およびその用途 |
| CN111393404B (zh) * | 2019-01-02 | 2023-02-17 | 中国科学院上海药物研究所 | 一类苯并噻吩类化合物及其药物组合物及应用 |
| CN113121527B (zh) * | 2019-12-31 | 2024-09-06 | 上海辉启生物医药科技有限公司 | 三环类化合物及其用途 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1099355B (it) | 1978-10-12 | 1985-09-18 | Sclavo Inst Sieroterapeut | Composizione adatta alla determinazione in cinetica del glucosio |
| JPS6188884A (ja) * | 1984-10-04 | 1986-05-07 | Sankyo Co Ltd | エンケフアリナ−ゼｂ阻害物質およびその製法 |
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| IT1264860B1 (it) * | 1993-06-21 | 1996-10-17 | Guidotti & C Spa Labor | Derivati di acidi cis- e trans-2(((2-(isdrossiammino)-2-ossoetil)- alchilammino)carbonil)cicloesancarbossilici |
| US6204293B1 (en) * | 1995-11-06 | 2001-03-20 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
| AU4249700A (en) * | 1999-04-19 | 2000-11-02 | Sumitomo Pharmaceuticals Company, Limited | Hydroxamic acid derivative |
| BR0014254A (pt) | 1999-09-08 | 2002-08-27 | Sloan Kettering Inst Cancer | Nova classe de agentes de citodiferenciação e inibidores de desacetilase de histona, e métodos de uso dos mesmos |
| KR20100035666A (ko) | 1999-11-23 | 2010-04-05 | 메틸진 인크. | 히스톤 디아세틸라제의 억제제 |
| GB0003476D0 (en) | 2000-02-16 | 2000-04-05 | British Biotech Pharm | Acetal Hydroxylamine compounds |
| JP2003528074A (ja) | 2000-03-24 | 2003-09-24 | メチルジーン インコーポレイテッド | ヒストン脱アセチル化酵素の阻害剤 |
| PE20020354A1 (es) * | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| GB0023983D0 (en) | 2000-09-29 | 2000-11-15 | Prolifix Ltd | Therapeutic compounds |
| EP2292593A3 (en) | 2000-09-29 | 2011-05-25 | TopoTarget UK Limited | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |
| CA2423868C (en) | 2000-09-29 | 2011-06-07 | Prolifix Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
| AR035513A1 (es) | 2000-12-23 | 2004-06-02 | Hoffmann La Roche | Derivados de tetrahidropiridina, proceso para prepararlos, composiciones farmaceuticas que los contienen, y uso de dichos compuestos en la preparacion de medicamentos |
| DE10295684T9 (de) | 2001-01-12 | 2004-10-14 | Methylgene, Inc., Saint-Laurent | Verfahren zum spezifischen Hemmen von Histon-Deacetylase-4 |
| US6784173B2 (en) | 2001-06-15 | 2004-08-31 | Hoffmann-La Roche Inc. | Aromatic dicarboxylic acid derivatives |
| JP2005517007A (ja) | 2002-02-07 | 2005-06-09 | アクシス・ファーマスーティカルズ | ヒストンデアセチラーゼ阻害剤としての新規二環式ヒドロキサメート |
| CA2476583C (en) | 2002-03-13 | 2011-07-05 | Kristof Van Emelen | Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
| JP4648628B2 (ja) | 2002-03-13 | 2011-03-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストンデアセチラーゼの新規な阻害剤としてのカルボニルアミノ誘導体 |
| ES2306859T3 (es) | 2002-03-13 | 2008-11-16 | Janssen Pharmaceutica Nv | Derivados de sulfonil como nuevos inhibidores de histona deacetilasa. |
| WO2003076401A1 (en) | 2002-03-13 | 2003-09-18 | Janssen Pharmaceutica N.V. | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase |
| NZ536116A (en) | 2002-04-03 | 2007-01-26 | Topotarget Uk Ltd | Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors |
| TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
| GB0209715D0 (en) | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| KR20050034732A (ko) | 2002-08-02 | 2005-04-14 | 아젠터 디스커버리 리미티드 | 히스톤 디아세틸라제 억제제로서의 치환된티에닐-히드록사믹산 |
| US7221775B2 (en) | 2002-11-12 | 2007-05-22 | Intellivid Corporation | Method and apparatus for computerized image background analysis |
| PT1611088E (pt) | 2003-04-07 | 2009-09-24 | Pharmacyclics Inc | Hidroxamatos como agentes terapêuticos |
| WO2004110989A1 (en) | 2003-05-14 | 2004-12-23 | Bayer Pharmaceuticals Corporation | N-hydroxy-7-(arylamino)heptanamide derivatives useful for treating hyper-proliferative disorders |
| EP1633751A1 (en) * | 2003-06-16 | 2006-03-15 | Chroma Therapeutics Limited | Carboline and betacarboline derivatives for use as hdac enzyme inhibitors |
| EP1644323B1 (en) | 2003-07-07 | 2015-03-18 | Georgetown University | Histone deacetylase inhibitors and methods of use thereof |
| WO2005004861A1 (en) | 2003-07-15 | 2005-01-20 | Korea Research Institute Of Bioscience And Biotechnology | A use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same |
| WO2005014588A1 (en) | 2003-08-01 | 2005-02-17 | Argenta Discovery Limited | Substituted thienyl-hydroxamic acids having histone deacetylase activity |
| US20060270730A1 (en) | 2003-08-07 | 2006-11-30 | Andreas Katopodis | Histone deacetylase inhibitors as immunosuppressants |
| MXPA05011286A (es) | 2003-08-20 | 2006-01-24 | Axys Pharm Inc | Derivados de acetileno como inhibidores de histona deacetilasa. |
| HRP20060080A2 (en) | 2003-08-26 | 2006-07-31 | Sloan-Kettering Institute For Cancer Research | Method of treating cancer with hdac inhibitors |
| KR101127201B1 (ko) | 2003-09-22 | 2012-04-12 | 에스*바이오 피티이 리미티드 | 벤즈이미다졸 유도체와 그의 제조방법 및 약학적 적용 |
| AU2004276337B2 (en) | 2003-09-24 | 2009-11-12 | Methylgene Inc. | Inhibitors of histone deacetylase |
| AU2004280264A1 (en) | 2003-10-09 | 2005-04-21 | Merck Hdac Research, Llc | Thiophene and benzothiophene hydroxamic acid derivatives |
| JP2007509082A (ja) * | 2003-10-22 | 2007-04-12 | アルピダ エー／エス | ペプチドデホルミラーゼ阻害剤としてのベンゾイミダゾール誘導体類およびそれらの使用 |
| MX2007013257A (es) | 2005-05-05 | 2008-01-21 | Chroma Therapeutics Ltd | Conjugados de ester de alfa-aminoacido-farmaco hidrolizables por carboxilesterasa. |
| GB0509223D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
-
2005
- 2005-05-05 GB GB0509223A patent/GB0509223D0/en not_active Ceased
-
2006
- 2006-05-04 NZ NZ560289A patent/NZ560289A/en not_active IP Right Cessation
- 2006-05-04 EP EP06726982A patent/EP1879895B1/en not_active Expired - Lifetime
- 2006-05-04 BR BRPI0607410-3A patent/BRPI0607410A2/pt not_active Application Discontinuation
- 2006-05-04 EP EP20100176446 patent/EP2301939A1/en not_active Withdrawn
- 2006-05-04 KR KR1020077019886A patent/KR101307815B1/ko not_active Expired - Fee Related
- 2006-05-04 PT PT06726982T patent/PT1879895E/pt unknown
- 2006-05-04 CN CN2006800069161A patent/CN101133060B/zh not_active Expired - Fee Related
- 2006-05-04 PL PL06726982T patent/PL1879895T3/pl unknown
- 2006-05-04 DK DK06726982.9T patent/DK1879895T3/da active
- 2006-05-04 AU AU2006243065A patent/AU2006243065B2/en not_active Ceased
- 2006-05-04 ES ES06726982T patent/ES2367369T3/es not_active Expired - Lifetime
- 2006-05-04 CA CA2599411A patent/CA2599411C/en not_active Expired - Fee Related
- 2006-05-04 US US11/918,139 patent/US7939666B2/en active Active
- 2006-05-04 WO PCT/GB2006/001605 patent/WO2006117549A1/en not_active Ceased
- 2006-05-04 JP JP2008509500A patent/JP5405820B2/ja not_active Expired - Fee Related
- 2006-05-04 MX MX2007010456A patent/MX2007010456A/es active IP Right Grant
- 2006-05-04 AT AT06726982T patent/ATE512150T1/de active
-
2007
- 2007-08-22 ZA ZA200707091A patent/ZA200707091B/xx unknown
- 2007-08-29 IL IL185580A patent/IL185580A/en active IP Right Grant
-
2010
- 2010-12-01 US US12/957,829 patent/US8686032B2/en not_active Expired - Fee Related
-
2014
- 2014-02-13 US US14/179,880 patent/US9133104B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240002360A1 (en) | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | |
| WO2023078021A1 (en) | Bcma monoclonal antibody and the antibody-drug conjugate | |
| US11890281B2 (en) | SHP2 phosphatase inhibitors and methods of making and using the same | |
| CN103429574B (zh) | 作为蛋白质去乙酰化酶抑制剂的嘧啶羟基酰胺化合物和其使用方法 | |
| US11547759B2 (en) | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | |
| CN105814028B (zh) | 作为免疫调节剂的1，2，4‑*二唑衍生物 | |
| AU582600B2 (en) | Dipeptide compounds having pharmaceutical activity and compositions containing them | |
| JP2021519794A (ja) | 縮合二環式Ｃ５ａＲアンタゴニストのプロドラッグ | |
| JP2010505802A5 (enExample) | ||
| JP2025011095A (ja) | パンテテイン誘導体及びその使用 | |
| JP2012516896A5 (enExample) | ||
| CA3003271A1 (en) | Compositions and methods for inhibiting arginase activity | |
| JP2022541749A (ja) | 治療薬としての細胞毒素のペプチドコンジュゲート | |
| TW201313725A (zh) | ６Ｈ－噻吩并［３，２－ｆ］［１，２，４］三唑并［４，３－ａ］［１，４］二氮呯 | |
| TW201735926A (zh) | 作為蛋白質去乙醯酶抑制劑之反式醯胺化合物及其使用方法 | |
| AU2017356942A1 (en) | Arginase inhibitor combination therapies | |
| JP2010507639A5 (enExample) | ||
| JP2009535387A5 (enExample) | ||
| AU2013209952B2 (en) | New forms and salts of a dihydropyrrolo(1,2-c)imidazolyl aldosterone synthase or aromatase inhibitor | |
| UA95916C2 (ru) | Производные хинолина как антибактериальные средства | |
| CZ2003487A3 (cs) | Inhibitory alfa 4 zprostředkované buněčné adheze | |
| US20140205681A1 (en) | HYDROGEN-BOND SURROGATE PEPTIDES AND PEPTIDOMIMETICS FOR p53 REACTIVATION | |
| JP2022522312A (ja) | ピロール化合物 | |
| US11566002B2 (en) | Substituted tetrahydrocyclopenta[C]pyrroles, substituted dihydropyrrolizines, analogues thereof, and methods using same | |
| JP2014511865A5 (enExample) |